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Abstract: Mutations of the KIT gene are the molecular hallmark of most gastrointestinal stromal 
tumors (GISTs). GIST has become a model for targeted treatment of solid tumors, imatinib 
becoming the standard first-line treatment of these tumors in the advanced/metastatic phase. 
Because of the efficacy of imatinib treatment in the advanced setting, its role following resection 
of a primary non-metastatic GIST was investigated. The recently published phase III, double-
blind, placebo-controlled, multicenter ACOSOG Z9001 study showed that adjuvant therapy 
is safe, and significantly improves recurrence-free survival compared to placebo when given 
after resection. To what extent imatinib will improve overall survival has yet to be answered. 
What is clear is that high-risk GIST patients definitely need adjuvant therapy, and that 1 year 
of imatinib is not enough for the patients who do need it. The questions of optimal duration 
of imatinib treatment in the adjuvant setting, adequate selection of risk patients and effect of 
imatinib on overall survival are currently being studied.
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Introduction
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of 
the gastrointestinal (GI) tract,1 with an annual incidence of approximately 7 to 19 
cases per million.2–4 They are thought to be derived from the interstitial cells of Cajal 
or a common precursor, based on immunohistochemical and ultrastructural data. 
They account for 1% of all GI tumors.5 GISTs affect men slightly more often than 
women. At the time of diagnosis, the majority of patients are aged 40 to 80 years with 
a median of 60 years.3 They may arise anywhere along the GI tract, but they are most 
commonly found in the stomach (60%) and small intestine (25%).6 Less frequently, 
GISTs are found in the rectum, esophagus or rarely at extragastrointestinal sites such 
as the omentum or mesentery. As clinical presentation of GIST is variable, diagnosis 
can be challenging in some cases. GISTs are often asymptomatic and discovered 
incidentally. When symptoms do arise, they depend on the location and size of the 
tumor. Signs or symptoms of GIST include early satiety, bloating, vague abdominal 
pain or discomfort, weight loss, nausea, GI hemorrhage, a palpable abdominal mass, 
and additional GI complaints. GI bleeding is the most common sign of GIST, and 
while fatigue from anemia is a frequent symptom indicative of chronic bleeding, acute 
hemorrhage can also occur.7
Most GISTs are sporadic, although a few families with germline mutations have 
been reported with KIT mutation or platelet-derived growth factor α (PDGFRα) 
mutation.8,9 Activating mutations of KIT and less commonly PDGFRα, which 
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encode the stem-cell factor receptor (KIT) and PDGFRα 
tyrosine kinases, respectively, are believed to be pivotal 
in the molecular pathogenesis.10 Such activating mutations 
cause constitutive activation of the tyrosine kinase activity of 
these receptors and consequently activation of downstream 
signaling pathways. GISTs exhibit activating KIT mutations 
in 80% to 85% of cases. The remaining tumors (10% to 15%) 
either exhibit an activating mutation of the PDGFRα gene, 
or show no mutations of these two genes. This latter group 
is generally referred as to as “wild type” GIST.10
Once diagnosed, the curative treatment of a primary GIST 
is based on surgical excision of the tumor. The aim of the 
procedure is to achieve complete en bloc resection of the 
lesion, with clear R0 margins, and to avoid tumor rupture or 
spillage. Recurrence following surgery has been reported in 
11% to 56% of patients in previous retrospective series.11–14 
The risk of recurrence following adequate surgical resection 
depends on histological features (mitotic index), tumor size, 
and location.15,16 GISTs recur in the abdominal cavity or as 
liver metastases, rarely in the lung or bones.
Before imatinib, the prognosis for patients with recurrent 
or metastatic GIST was very poor, with a median overall 
survival (OS) of 9 to 18 months in most series. The develop-
ment of imatinib mesylate has revolutionized the manage-
ment of patients with locally advanced and metastatic GIST, 
leading to important gains in quality of life and survival. 
Several multi-institutional studies, with a total of more than 
1800 enrolled patients, have now evaluated the efficacy of 
imatinib treatment of advanced/metastatic GIST. Imatinib 
was proven to significantly improve progression-free survival 
(PFS) and OS, with a median PFS of approximately 2 years 
and a median OS of nearly 5 years.17 Indeed these results 
come from the early studies, which were carried out early 
on the use of imatinib for GIST in the medical community 
and had an obvious unfavorable case mix, with several 
patients carrying high tumor volumes. In fact, treatment 
with imatinib achieves disease control in the majority of 
patients with metastatic GIST (80% to 90%) regardless of 
tumor size,17–21 but tumor size does have an adverse effect 
on time to progression.22 Imatinib approval for the systemic 
treatment of advanced/metastatic GIST in 2002 was a major 
advance in the therapeutic management of these patients. All 
current guidelines, including those of the European Society of 
Medical Oncology and the National Comprehensive Cancer 
Network, recommend imatinib as the standard of care in the 
first-line management of unresectable or metastatic GIST.10,23 
A combined analysis of the two international EORTC and 
SWOG phase III trials (MetaGIST) showed that patients 
with mutations in exon 9 of KIT have a significantly longer 
PFS with high-dose (800 mg) imatinib therapy compared to 
standard dose (400 mg).21
Pharmacology, pharmacokinetics 
and drug–drug interaction
Imatinib mesylate (formerly referred to as STI 571, 
now Glivec® [Europe], Gleevec® [US]; Novartis) is a 
2-phenilpyrimidine derivative, a small, orally bioavail-
able molecule that competitively binds to the adenos-
ine triphosphate-binding pocket of certain tyrosine 
kinases, including c-kit, c-ABL, bcr-ABL, and PDGFRα, 
thereby inhibiting kinase activity and causing interrup-
tion of the downstream signaling process that leads to cell 
  proliferation.5,24,25
The pharmacokinetic profile of imatinib in patients with 
GIST is comparable to that seen in healthy volunteers, and 
in patients with chronic myelogenous leukemia (CML).7 
Imatinib has a good oral absorption and a bioavailability of 
about 98%, regardless of the preparation (solution, capsule, 
or tablet) or dosage strength (100 mg, 400 mg).26 Food does 
not affect imatinib absorption.27 Once absorbed, it highly 
binds to serum proteins (mainly albumin and alpha 1-acid 
glycoprotein). Peak plasma levels of imatinib occur in about 
4 hours, and levels reach steady state within a week.7 The main 
circulating metabolite is an N-demethylated piperazine deriva-
tive which accounts for 16% of the AUC (area under curve) 
for imatinib. This accounts for most of the imatinib activity, 
but there are a number of smaller metabolites. Most of the 
drug is metabolized by the cytochrome P450 isoenzyme 3A4 
(CYP3A4), so co-administered drugs that induce or inhibit 
this enzyme may increase or decrease clearance of imatinib, 
respectively. Concomitant administration of CYP3A4 inhibi-
tors (eg, ketoconazole) may increase and CYP3A4 inducers 
(eg, Hypericum [St. John’s wort], rifampicin) may decrease 
imatinib systemic exposure (Cmax and AUC).28 Conversely, 
imatinib is a moderate inhibitor of CYP3A4 and may increase 
exposure to drugs metabolized by this isoenzyme, such as some 
statins.28,29 Furthermore imatinib has been shown to be potent 
competitive inhibitor of CYP2C9, CYP2D6 and CYP3A5; con-
comitant imatinib administration may result in elevated blood 
concentrations of drugs that are substrates of these enzymes.27 
Imatinib may increase systemic exposure to paracetamol by 
inhibiting its O-glucorunidation.27 The terminal elimination 
half-life is approximately 18 hours, which allows for once a 
day dosage. Excretion is via the feces and urine, the majority 
being the metabolites. Age, race, sex, and bodyweight do not 
significantly affect the pharmacokinetics of the drug.26Clinical and Experimental Gastroenterology 2010:3 43
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Safety and tolerability and 
management of adverse events
Phases II and III clinical trials on advanced/metastatic GISTs 
demonstrated that imatinib was generally well tolerated at 
doses up to 800 mg daily. Similar to the findings in CML trial 
patients, most adverse events in patients receiving imatinib 
for GIST were minor and manageable without the need for 
dose adjustment. Almost all patients (≈99%) experienced 
adverse events; however, most of the events were of mild19 
or mild to moderate20 severity. The most commonly reported 
side effects included edema (usually periorbital), anemia, 
diarrhea, nausea/vomiting, abdominal pain, muscle aches, 
fatigue, and rash.18,20 The incidence of serious adverse events 
was similar for the imatinib 400 and 800 mg/day groups (37% 
and 38% of patients) in the EORTC phase III trial.19 The 
side effect profile of imatinib may improve with prolonged 
therapy.19 In an analysis of the tolerability profile before 
versus after crossover from the 400 to the 800 mg/day arm 
(in the EORTC phase III trial), the incidences of anemia and 
fatigue were significantly increased, with 12.8% (P = 0 .015 
versus before crossover) and 7.5% (P = 0.00001) of patients 
experiencing new grade ¾ events.30 On the other hand, no 
increase in grade 3–4 neutropenia was documented after 
crossover to the higher dosage (P = 0.002).30 Imatinib was 
generally well tolerated following long-term administration 
in GIST patients, according to tolerability data obtained from 
the US phase II study in which patients were followed up for 
a median of 41 months while receiving imatinib.17
Efficacy
Given the high risk of relapse following surgery for local-
ized GISTs, especially for larger GISTs, and the efficacy of 
imatinib mesilate in the advanced setting, as well as its favor-
able safety profile, investigators hypothesized that imatinib 
mesilate given postoperatively after gross complete resec-
tion of primary GIST could delay or prevent recurrence and 
therefore improve survival. Furthermore, as the development 
of imatinib resistance appears to be due to the emergence 
or expansion of individual clones, the risk of developing 
such resistant clones might be reduced by using imatinib at 
an earlier stage. Thus a number of clinical trials have been 
investigating the merits of using adjuvant imatinib therapy.
The ACOSOG Z9000 phase II study addresses treat-
ment with imatinib (400 mg/day orally) for 1 year, in 
patients with high-risk GIST (tumor size 10 cm, rupture, 
or 5 peritoneal metastases) who had undergone complete 
resection with no control arm. The results of this trial indicate 
that imatinib is associated with improved OS in comparison 
with historical controls. However, these controls refer to the 
era when imatinib was not available even for patients with 
advanced disease. The study enrolled 107 evaluable patients, 
with a median tumor size of 13 cm (3–42 cm). Eighty-seven 
patients (82%) completed the full year of imatinib therapy. 
Seventy-two patients (68%) tolerated full dose imatinib 
without dose modification, 8 had a temporary dose reduc-
tion, and 7 finished at a lower dose.31,32 This phase II study 
confirmed the favorable safety profile of imatinib therapy in 
this setting. The 1-, 2-, and 3-year relapse-free survival (RFS) 
rates were 94%, 73%, and 61%, respectively.32 Nilsson and 
colleagues33 reported their own experience with adjuvant 
imatinib of a single-center, in a consecutive pilot series of 
23 patients with high-risk GIST who have been treated with 
adjuvant imatinib (400 mg/daily for 1 year) after R0 resec-
tion. These cases were compared with historical controls 
from previous population-based series treated with surgery 
alone. This study shows that 1-year treatment of imatinib 
after R0 resection for high-risk GIST dramatically reduces 
the risk of recurrent disease. The results of this study and of 
the ACOSOG Z9000 study await confirmation from prospec-
tive adjuvant treatment trials.
Three randomized trials have been initiated to investigate 
the role of a 400 mg daily dose of imatinib, given for 1 year 
versus placebo (ACOSOG Z9001) with RFS as the primary 
end-point, for 2 years versus observation alone (Intergroup 
GEIS/EORTC/ISG/FSG/AGITG 62024) with OS as the 
primary end-point or for 3 years versus 1 year in the SSG 
XVIII/AIO trial with RFS as the primary end-point.
Until the reporting of the ACOSOG Z9001 study con-
sensus, clinical practice guidelines recommend including 
patients with resected non-metastatic disease in clinical trials 
of adjuvant therapy.10,34,35
The ACOSOG Z9001 trial was presented at ASCO meet-
ing 2007, and preliminary data demonstrated a significant 
improvement in RFS, but not of OS, in patients with tumors 
3 cm in diameter (hazard ratio in favor of imatinib 0.35 
(95% confidence interval 0.22–0.53).36 The study enrolled 
713 patients with localized GIST having a diameter greater 
than 3 cm.36 At the median follow-up of 19.7 months, 8% of 
patients in the imatinib group and 20% in the placebo group 
had recurrence or died. Imatinib significantly improved RFS 
compared with placebo (98% versus 83% at 1 year). In the 
updated report37 the difference in RFS was significant for all 
size subgroups (ie, 3–6 cm, 6–10 cm, and 10 cm). Adjuvant 
imatinib was well tolerated. Grade 1 and 2 events were com-
mon, and mostly involved GI effects (mild diarrhea, nausea 
and flatulence), headache, rash, periorbital or peripheral Clinical and Experimental Gastroenterology 2010:3 44
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edema, fatigue, or myalgias or arhralgias. Two hundred and 
fifty-one patients (73%) in the placebo group and 229 (68%) 
in the imatinib group had a grade 1 or 2 event. Grade 3 or 4 
events occurred in 63 (18%) patients in the placebo group and 
104 (31%) in the imatinib group, the most common serious 
adverse events being dermatitis, abdominal pain and diar-
rhea in the imatinib group, and hyperglycemia in the placebo 
group.37 Adjuvant imatinib therapy is safe and improves RFS 
compared with placebo after the resection of primary GIST. 
No significant effect on OS was observed, because of the 
limited follow-up time, the limited number of relapses, the 
crossover design of the study which allowed patients assigned 
to the placebo group to receive imatinib on recurrence, and 
the considerably improved survival of patients in metastatic 
phase with imatinib.37 These updated results of this trial led 
to the Food and Drug Administration marketing approval 
(December 2008) of imatinib for the treatment of GIST in 
the adjuvant setting without definite guidance as to optimal 
duration of treatment or which patients should be most 
likely to benefit. The European Medicines Agency (EMEA) 
approved the use of adjuvant imatinib in March 2009. EMEA 
approval is restricted to patients at significant risk of relapse, 
without reference to what criteria should be used to make 
determination. Because of the potential toxic effects and the 
financial cost of the treatment, the ability to measure risk of 
recurrence for individual patients is important. The other 
phase III studies have just been completed, and results have 
therefore not been reported. At this stage several questions 
remain unanswered.
Delay or prevention?
The major question of whether adjuvant therapy will prevent 
relapse or only delay it remains unclear. In view of the 
observations gathered in advanced disease from the French 
BFR14 trial in particular, imatinib interruption at either 
1 or 3 years is followed consistently by relapse at a median 
of 6 months.38,39 Although these are the only data available 
so far, a complete analogy with the adjuvant setting should 
be taken with caution. Yet it is possible that relapse may only 
be delayed, and not prevented, in the adjuvant setting, and 
the current survival curves in the ACOSOG Z9001 cannot 
exclude this possibility.
Overall survival
The aim of any adjuvant treatment is both to reduce the 
risk of relapse and, in particular, to increase OS. Therefore, 
today’s ACOZOG Z9001 study is a self-fulfilling prophecy 
only. Patients with a high-risk of metastatic spread were given 
treatment with a highly effective drug which, unsurprisingly, 
yielded an improved RFS compared with placebo while 
receiving treatment. Whether this advantage translates into 
improved survival has yet to be shown. In the ACOSOG 
Z9001 study, OS did not differ between groups. Given the 
relatively limited risk of death from GIST in the first years 
following the initiation of imatinib for advanced disease, it is 
likely that the effect of adjuvant treatment on OS, if any, will 
not be apparent until 7 or 8 years following the completion 
of the EORTC 62024 trial.
Patient selection
The question of which patient population will benefit most 
from adjuvant imatinib is an important one. Accurate risk 
stratification is crucial for the selection of patients who 
are most likely to benefit from adjuvant imatinib therapy, 
initially in clinical trials and ultimately in clinical practice. 
It is known that multiple factors affect patient risk, including 
mitotic index, tumor size, site, mutation type, completeness 
of surgery, and rupture,16,40–43 but risk stratification with 
an optimal staging system has not been established and 
validated.3,15,41,44–46 Two commonly used staging systems for 
prognosis were developed at a 2001 US National Institutes 
of Health (NIH) workshop (Table 1).15,44 A modification 
of one of these staging systems was then suggested in 
2006 (Table 1).40 None of these staging systems provides a 
quantifiable risk of recurrence for individual patients. Gold 
and colleagues47 recently developed and validated a nomo-
gram to predict RFS after resection of localized primary 
GIST. The nomogram, which takes into account tumor size 
(cm), location (stomach, small intestine, colon/rectum, or 
other), and mitotic index (5 or 5 mitoses per 50 high-
power fields) has better predictive accuracy, as determined by 
concordance probabilities, than two commonly used staging 
systems developed at the US NIH GIST workshop in 2001. 
It has a similar probability of concordance with the third stag-
ing system, Miettinen’s Armed Forces Institute of Pathology 
(AFIP) system.40 Nomogram predictions of RFS seems better 
calibrated than predictions made with the Miettinen AFIP 
system. The inclusion of tyrosine kinase mutation status in 
the nomogram do not improve its discriminatory ability. The 
nomogram might be useful for patient care, interpretation of 
clinical trial results, and selection of patients for adjuvant 
imatinib therapy.
In 2008, Joensuu42 proposed modifying the NIH consen-
sus classification (based on tumor size and mitotic count) by 
introducing two important risk stratification factors in the NIH 
classification: site of origin and rupture. The modification of Clinical and Experimental Gastroenterology 2010:3 45
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the NIH classification could be useful in selecting adult 
patients for clinical trials of adjuvant systemic treatment, and 
subsequently, if validated, for identifying which patients are 
most likely to benefit from adjuvant therapy.42
Standard of care for localized primary GIST after sur-
gical resection has changed recently on the basis of the 
results of the ACOSOG Z9001 trial. The ACOSOG Z9001 
trial was powered on RFS on the entire study population, 
which consisted of patients with tumors of 3 cm or more. 
Nevertheless, ad hoc analysis of size (which was the only 
stratification factor) showed significant differences in RFS 
between imatinib and placebo groups in each size category 
(ie, 3–6 cm, 6–10 cm, and 10 cm).37 Retrospective analysis 
of mitotic index assessed by central pathology review and 
location is underway.47 Once additional follow-up data and 
more events are obtained, further validation of the nomogram 
using the patients assigned to the placebo group should be 
done in the ACOSOG Z9001 study. Patients at low risk of 
recurrence might not need adjuvant imatinib. However, 
patients at high risk of relapse need postoperative therapy 
for periods longer than 1 year
Duration of treatment
The optimal duration of adjuvant imatinib is not known, 
and the only available data show the efficacy of 1-year 
treatment on RFS. Further clinical trials, which have already 
fully accrued, should address this issue satisfactorily. Two 
phase III trials aim to answer some of the outstanding 
questions on imatinib adjuvant therapy, the EORTC 62024 
and SSG XVIII trials. The EORTC 62024 clinical trial is a 
controlled randomized trial comparing adjuvant imatinib 
(400 mg daily) for 2 years versus no further therapy after 
complete surgery for intermediate- and high-risk patients 
with localized, completely resected GIST expressing KIT. 
In this study the risk stratification is based on both size 
and mitotic index. Target accrual of 900 patients has been 
reached. The primary end-point is OS, with RFS, relapse-
free interval, and safety as secondary end-points. Follow-
ing the early interruption of the ACOSOG Z9001 trial, 
another secondary end-point was added: time to imatinib 
failure. Logically, this end-point provides a good surrogate 
for definitive efficacy of adjuvant therapy. This trial will 
also provide important information on the question of the 
optimal treatment duration.
The SSG XVIII study is an open-label, randomized, 
prospective, phase III trial, and includes patients with high-
risk GIST treated with imatinib (400 mg daily) for either 
1 or 3 years. The accrual target of 400 patients has been met. 
The primary objective is to investigate the RFS within the 
first 5 years following diagnosis. Secondary objectives are 
the investigation of feasibility of adjuvant imatinib therapy, 
OS, and GIST-specific survival. Although the results of the 
SSG XVIII/AIO trial comparing 1 versus 3 years are not yet 
available, it is likely that RFS will be better for the 3-year 
arm, since there is no reason to believe that the outcome of 
patients may be different in the minimal residual disease 
setting. However, only the SSG XVIII/AIO trial will provide 
a conclusive, reliable answer to the question of optimal 
duration of adjuvant therapy.
Table 1 Commonly used rating systems for assessing risk 
of GIST
  Features
NIH: Fletcher15
Very low 2 cm and 5 mitotic index
Low 2–5 cm and 5 mitotic index
Intermediate 5–10 cm and 5 mitotic index
5 cm and 6–10 mitotic index
High 5 cm and 5 mitotic index
10 cm and any mitotic index or
any size and 10 mitotic index
NIH: Miettinen44
Probably benign Gastric: 5 cm and 5 mitotic index
Intestinal: 2 cm and 5 mitotic index
Uncertain or low Gastric: 5 cm, 10 cm, and 5 mitotic 
index
Malignant potential Intestinal: 2 cm, 5 cm, and 5 mitotic 
index
Probably malignant Gastric: 10 cm or 5 mitotic index
Intestinal: 5 cm or 5 mitotic index
AFIP: Miettinen40
Very low, if any malignant 
potential
2 cm, and 5 mitotic index
Low malignant potential Gastric: 2 cm and 10 cm, and 5 
mitotic index; 2 cm, and 5 mitotic 
index
Intestinal: 2 cm and 5 cm, and 5 
mitotic index
Intermediate Gastric: 10 cm and 5 mitotic index
Malignant potential 2 cm and 5 cm, and 5 mitotic index
Intestinal: 5 cm and 10 cm, and 5 
mitotic index
High malignant Gastric: 5 cm and 5 mitotic index
potential Intestinal: 10 cm or 5 mitotic index
Notes: mitotic index = number of mitoses per 50 high-power field.
Abbreviations: AFIP, Armed Forces Institute of Pathology; NIH, National Institutes 
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Dose
KIT exon 9 mutated tumors benefit from a 800 mg/day dose in 
an advanced phase, but the effect of such dose in the adjuvant 
setting has not yet been explored.21,48 Similarly, some (but not 
all) exon 18 PDGFRA mutations such as D842V , which are 
seen in gastric GISTs, appear to be relatively indolent but are 
less likely to be as sensitive as GISTs with KIT mutations in 
the adjuvant setting, even though this needs to be formally 
explored, as data are available at this stage only in vitro and 
in a metastatic setting.49,50 The question of whether different 
molecular subtypes of GIST should receive different adjuvant 
treatment will need to be carefully addressed in the currently 
ongoing or completed studies.
Conclusion
From the studies conducted so far, it is clear that high-risk 
GIST patients need treatment, but we do not know to what 
extent imatinib will improve OS. It seems very likely that 
1 year of imatinib is not enough for those who do need it. The 
SSG XVIII and EORTC studies will help to answer the ques-
tion of the optimal duration treatment and survival. When the 
question of risk assessment by different criteria15,40,42 arises, 
the decision should always be made on the most stringent 
assessment. Today, physicians and patients are therefore put 
in a difficult situation of not having all the answers (ultimate 
benefit in terms of OS, optimal duration of treatment, pre-
vent or delay of relapse, and so on) with which to make a 
meaningful and scientifically based decision.
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